An open trial of olanzapine in anorexia nervosa.

Department of Psychiatry, University of Pittsburgh Medical School, Anorexia and Bulimia Nervosa Research Module, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 12/2004; 65(11):1480-2. DOI: 10.4088/JCP.v65n1106
Source: PubMed

ABSTRACT Recent reports raise the possibility that olanzapine can assist weight gain and improve behavioral symptoms during refeeding in anorexia nervosa.
Seventeen DSM-IV anorexia nervosa subjects hospitalized between May 1999 and October 2000 were enrolled in open-label treatment with olanzapine for up to 6 weeks. Baseline weight and symptoms were compared to patients' status at the end of treatment.
Olanzapine administration was associated with a significant reduction in depression, anxiety, and core eating disorder symptoms, and a significant increase in weight. A comparison with our historical data suggests that subjects in this study had a significantly greater decrease in depression.
These data lend support to the possibility that olanzapine may be useful in treating anorexia nervosa. However, a controlled trial is necessary to demonstrate that olanzapine is efficacious.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Methods to reduce gamma-ray sensitivity of a liquid scintillator EJ309 have been studied. Zero-crossing pulse shape discrimination method was used to separate events generated by neutron and gamma radiation between 60−keVee and 4MeVee. The measurements were carried out under irradiation from an intense 137Cs source, yielding dose rate of 10mR/h at the detector. A Pu–Be source was used to establish neutron integration window. Pile-up rejection (PUR) circuit was used to reduce gamma-ray induced events under irradiation from an intense gamma-ray source. Further, application of lead, tin and copper shields was done in order to decrease intrinsic gamma-neutron detection efficiency.
    Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment 10/2011; 652(1):330-333. · 1.32 Impact Factor
  • Source
    Child and Adolescent Psychopharmacology News 11/2005; 10(7):1-4.
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: During the last 10 years, the use of psychotropic medications in youth with psychiatric disorders, including eating disorders, has significantly increased, but their role in the treatment of adolescent anorexia nervosa is still controversial. OBJECTIVE: This paper aims to review the literature on the use of antidepressants and antipsychotics in adolescents with anorexia nervosa, comparing the efficacy and tolerability in this population with those reported in trials with patients not selected by age. METHOD: A systematic review of the available literature published so far. RESULTS: Only few studies met the selection criteria. No strong evidence of beneficial effects was found in using antidepressants and antipsychotics neither in adults nor in adolescents. Side effects were more frequently reported in studies including adolescent population. Among psychotropic drugs, the majority of studies focused on olanzapine, which seems to have, in some studies, only positive effects on body mass index, eating disorder symptoms and functional impairment in both age groups. Copyright © 2013 John Wiley & Sons, Ltd and Eating Disorders Association.
    European Eating Disorders Review 06/2013; 21(5). · 1.38 Impact Factor